Haemonetics Corporation (HAE): Price and Financial Metrics
HAE Stock Summary
- HAE's current price/earnings ratio is 86.06, which is higher than 91.9% of US stocks with positive earnings.
- The price/operating cash flow metric for Haemonetics Corp is higher than 93.96% of stocks in our set with a positive cash flow.
- Over the past twelve months, HAE has reported earnings growth of 89.92%, putting it ahead of 88.18% of US stocks in our set.
- Stocks that are quantitatively similar to HAE, based on their financial statements, market capitalization, and price volatility, are NUVA, TNC, ELY, TNET, and TZOO.
- Visit HAE's SEC page to see the company's official filings. To visit the company's web site, go to www.haemonetics.com.
HAE Stock Price Chart More Charts
HAE Price/Volume Stats
|Current price||$118.29||52-week high||$140.36|
|Prev. close||$119.46||52-week low||$80.24|
|Day high||$119.59||Avg. volume||501,169|
|50-day MA||$115.99||Dividend yield||N/A|
|200-day MA||$119.09||Market Cap||5.95B|
Haemonetics Corporation (HAE) Company Bio
Haemonetics designs, manufactures, and markets blood management solutions. The Company serves in three markets, such as manufacturers of plasma-derived pharmaceuticals, blood collectors, and hospitals. The company was founded in 1971 and is based in Braintree, Massachusetts.
HAE Price Forecast Based on DCF Valuation
|Current Price||DCF Fair Value Target:||Forecasted Gain:|
Below please find a table outlining a discounted cash flow forecast for HAE, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Haemonetics Corp ranked in the 17st percentile in terms of potential gain offered. Our DCF analysis suggests the stock is overvalued by about 83.33%. As for the metrics that stood out in our discounted cash flow analysis of Haemonetics Corp, consider:
- Interest coverage, a measure of earnings relative to interest payments, is 7.13 -- which is good for besting 61.11% of its peer stocks (US stocks in the Healthcare sector with positive cash flow).
- 94% of the company's capital comes from equity, which is greater than 81.84% of stocks in our cash flow based forecasting set.
- The business' balance sheet reveals debt to be 6% of the company's capital (with equity being the remaining amount). Approximately merely 18.12% of US stocks with free cash flow have a lower reliance on debt in their capital structure.
|Terminal Growth Rate in Free Cash Flow||Return Relative to Current Share Price|